Abemaciclib Ups Overall Survival in High-Risk Breast Cancer

Adding the CDK4/6 inhibitor abemaciclib to endocrine therapy significantly improves overall survival in node-positive, high-risk early breast cancer, in the extended follow-up of a landmark trial.

from Ob/Gyn & Women’s Health – Medscape https://www.medscape.com/viewarticle/abemaciclib-ups-overall-survival-high-risk-breast-cancer-2025a1000san
via IFTTT

robotic surgeon, gynecologic cancer treatment center, holistic oncologist

Design a site like this with WordPress.com
Get started